| ¿µ¹® | estrogen | ÇÑ±Û | ¿¡½ºÆ®·Î°Õ |
|---|---|---|---|
| ¼³¸í | ³¼Ò¾È¿¡ ÀÖ´Â ³Æ÷¿¡¼ ºÐºñµÇ´Â ³Æ÷È£¸£¸óÀÇ ÃÑĪ. ¿©Æ÷È£¸£¸ó, ¹ßÁ¤ È£¸£¸óÀ̶ó°íµµ ÇÑ´Ù. ¿¡½ºÆ®·Î°ÕÀ̶õ »ý¹°ÇÐÀûÀÎ ¸íĪÀÌ¸ç µ¿¹°ÀÇ ¹ßÁ¤ÀÛ¿ë ¿Ü¿¡ ¿©·¯ °¡Áö ÀÛ¿ëÀ» Áö´Ñ ¹°ÁúÀÇ ÃÑĪÀÌ´Ù. »ç¶÷¿¡´Â 20Á¾ ÀÌ»óÀÇ ¿¡½ºÆ®·Î°ÕÀÇ Á¾·ù°¡ ÀÖÁö¸¸, ±×Áß¿¡¼µµ estrone, estradiol, estriolÀÇ 3°¡Áö°¡ °¡Àå Áß¿äÇÏ´Ù. ¿¡½ºÆ®·Î°ÕÀº ºñÀӽŽÿ¡´Â ¿©Æ÷È£¸£¸óÀÇ Á¶Àý¿¡ ÀÇÇØ¼, ÁÖ·Î ³¼Ò¿¡¼ »ý¼ºµÇ¸ç, ÀӽŽÿ¡´Â ÁַΠŹݿ¡¼ ¸¸µé¾îÁöÁö¸¸, estriolÀº žÆÀÇ ºÎ½Å°ú ŹÝÀÇ ÇÕµ¿ÀÛ¿ë¿¡ ÀÇÇØ¼ ¸¸µç´Ù. »ç¶÷¿¡°Ô ÀÖ¾î¼ ¿¡½ºÆ®·Î°ÕÀÇ ÁÖµÈ ÀÛ¿ëÀº ´ÙÀ½°ú °°Àº °ÍÀÌ ÀÖ´Ù. 1. Á¦ 2Â÷ ¼ºÂ¡ÀÇ ¹ßÇö. 2. ³»¼º±â, Áú, ¿Ü¼º±âÀÇ ¹ßÀ°ÃËÁø 3. Àڱ󻸷 ¹× ¼º±â »óÇÇÀÇ Áõ½Ä 4. ¹è¶õ±â¿¡ ÀÚ±ÃÀÇ ÀÔ±¸ÀÎ ¸ñ¿¡ Á¡¾×À» Áõ·®½ÃÄÑ Á¤ÀÚÀÇ Åë°ú¼ºÀ» ÁÁ°Ô ÇÑ´Ù. 5. ÀӽŽÿ¡ ¼º±â¿Í À¯¹æ µî¿¡ Àӽżº º¯È¸¦ ÀÏÀ¸Å²´Ù. 6. ¼º±âÀÇ ±ÙÀ°À» Áõ½Ä½ÃÄÑ ¿îµ¿¼ºÀ» Áõ°¡½ÃŲ´Ù. 7. ´Ü¹éÁú ÁöÁú, ¹«±âÁú µîÀÇ ¹°Áú´ë»ç³ª ¿©·¯ °¡Áö È¿¼ÒÀÇ ÀÛ¿ë¿¡ ¿µÇâÀ» ÁØ´Ù. 8. ¹è¶õ°ú »ý¸® ÁÖ±âÀÇ À¯Áö¿¡ °ü¿©ÇÑ´Ù. |
||
| HCG, hCG | Human Chorionic Gonadotropin; »ç¶÷À¶¸ð¼º¼º¼±ÀÚ±ØÈ£¸£¸ó 1. Placental Glycoprotein Hormone &nbs... |
|---|---|
| E1 | Estrone; Æó°æÈÄ ÁÖµÈ Estrogen |
| E2 | Estradiole; Æó°æÀü ÁÖµÈ Estrogen |
| E3 | Estriol; ÀӽŽà ÁÖµÈ Estrogen °¡Àӱ⠿©¼º; E3/(E1 + E2) = 1 ÀӽŽà ¿©¼º; E3/(E1 + E2... |
| ER | 1) Emergency Room; ÀÀ±Þ½Ç 2) Estrogen Receptor |
| CCA | Calcium channel antagonists |
|---|---|
| H(2)RA | H(2) receptor antagonists |
| LTRA | Leukotriene receptor antagonists |
| AIIRA | angiotensin II receptor antagonists |
| E | Estrogen |
| estrogen | <endocrinology, hormone> A generic term for oestrus producing steroid compounds, the female sex hormones. In humans, oestrogen is formed in the ovary, possibly the adrenal cortex, the testis and the foetoplacental unit, it has various functions in both sexes. It is responsible for the development of the female secondary sex characteristics and during the menstrual cycle it acts on the female genitalia to produce an environment suitable for the fertilization, implantation and nutrition of the early embryo. Oestrogen is used in oral contraceptives and as a palliative in cancer of the breast after menopause and cancer of the prostate, other uses include the relief of the discomforts of menopause, inhibition of lactation and treatment of osteoporosis, threatened abortion and various functional ovarian disorders. (18 Nov 1997) |
|---|---|
| estrogen 2-hydroxylase | <enzyme> Same enzyme for hydroxylation in 2 or 4 position Registry number: EC 1.14.99.- Synonym: estrogen 4-hydroxylase, ethinylestradiol 2-hydroxylase (26 Jun 1999) |
| adrenergic alpha-antagonists | Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (12 Dec 1998) |
| adrenergic antagonists | Drugs that bind to but do not activate adrenergic receptors. Adrenergic antagonists block the actions of the endogenous adrenergic transmitters epinephrine and norepinephrine. (12 Dec 1998) |
| adrenergic beta-antagonists | Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (12 Dec 1998) |
| aldosterone antagonists | Compounds which inhibit or antagonise the biosynthesis or actions of aldosterone. (12 Dec 1998) |
| androgen antagonists | Compounds which inhibit or antagonise the biosynthesis or actions of androgens. (12 Dec 1998) |
| gaba antagonists | Drugs that bind to but do not activate gaba receptors, thereby blocking the actions of endogenous gaba or gaba agonists. (12 Dec 1998) |
| cholinergic antagonists | Drugs that bind to but do not activate cholinergic receptors, thereby blocking the actions of acetylcholine or cholinergic agonists. (12 Dec 1998) |
| muscarinic antagonists | Drugs that bind to but do not activate muscarinic cholinergic receptors (receptors, muscarinic), thereby blocking the actions of endogenous acetycholine or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. Antagonists that discriminate among the various muscarinic receptor subtypes and might allow better control of peripheral and central actions are under development. (12 Dec 1998) |
| heparin antagonists | Coagulant substances inhibiting the anticoagulant action of heparin. (12 Dec 1998) |
| prostaglandin antagonists | Compounds that inhibit the action of prostaglandins. (12 Dec 1998) |
| histamine antagonists | Drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonist. Classical antihistaminics block the histamine h1 receptors only. (12 Dec 1998) |
| histamine h1 antagonists | Drugs that selectively bind to but do not activate histamine h1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonise or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system h1 receptors are not as well understood. (12 Dec 1998) |
| histamine h2 antagonists | Drugs that selectively bind to but do not activate histamine h2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. (12 Dec 1998) |
Synonyms : Antagonists, Estrogen
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|